Physician profile
Michael Ducato
NPI 1265743272
$27,078.96
in general payments reported to CMS, 2019-2025
62 companies · $3,352 in 2025
The $3,352 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,069 · 2020: $1,215 · 2021: $3,359 · 2022: $2,058 · 2023: $8,769 · 2024: $7,256 · 2025: $3,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $7,542 · Travel and Lodging: $36.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,800.00 |
| Food and Beverage | $7,541.61 |
| Travel and Lodging | $36.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $13,826.29 | 2019-2025 | Repatha, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $2,290.46 | 2019-2025 | Spravato, Xarelto |
| Lilly USA, LLC | $1,434.32 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,313.51 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,167.16 | 2019-2025 | Jardiance |
| Abbvie INC. | $932.76 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $779.06 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $738.14 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $683.10 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $445.71 | 2019-2025 | |
| Antares Pharma, INC. | $351.25 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Exact Sciences Corporation | $282.42 | 2023-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $197.95 | 2022-2024 | Quviviq |
| Axsome Therapeutics, INC. | $189.21 | 2024-2025 | Auvelity, Symbravo |
| Endo Pharmaceuticals INC. | $179.47 | 2019-2021 |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $146.01 | 2019-2023 | Verquvo, Belsomra |
| Kowa Pharmaceuticals America, INC. | $129.78 | 2019-2020 | |
| Verity Pharmaceuticals INC. | $126.64 | 2024-2025 | Tlando |
| Amarin Pharma, INC. | $121.05 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $98.51 | 2019-2025 | Gattex, Trintellix |
| Abbott Laboratories | $90.40 | 2021-2025 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $88.71 | 2020-2025 | Austedo Xr |
| Allergan, INC. | $85.59 | 2020 | |
| Medline Industries Lp | $81.45 | 2019 | |
| Sanofi Pasteur INC. | $78.80 | 2022-2023 | |
| Horizon Therapeutics Plc | $73.21 | 2019-2023 | Krystexxa |
| Sumitomo Pharma America, INC. | $70.80 | 2024 | Gemtesa |
| Halozyme INC | $61.03 | 2023 | |
| Astellas Pharma US INC | $59.08 | 2019-2024 | Veozah |
| Janssen Biotech, INC. | $56.84 | 2021-2025 | Simponi Aria, Simponi, Stelara |
| Biomerieux INC | $56.61 | 2025 | Biofire Spotfire Control Station |
| Aimmune Therapeutics, INC. | $53.22 | 2024-2025 | Zenpep |
| Dexcom, INC. | $52.94 | 2023-2024 | Dexcom G6 Transmitter |
| Tolmar, INC. | $52.05 | 2024-2025 | Jatenzo |
| Biohaven Pharmaceuticals, INC. | $47.31 | 2021 | |
| Bioventus LLC | $39.73 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $39.15 | 2022 | |
| Corcept Therapeutics | $35.88 | 2025 | Korlym |
| Scilex Pharmaceuticals INC. | $35.82 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.71 | 2024-2025 | Xifaxan |
| Esperion Therapeutics, INC. | $32.97 | 2025 | Nexletol |
| Shield Therapeutics INC | $32.67 | 2024 | |
| Azurity Pharmaceuticals, INC. | $32.27 | 2025 | Azmiro |
| Convatec INC. | $29.88 | 2025 | |
| Inari Medical, INC. | $25.38 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Viatris Specialty LLC | $22.52 | 2025 | Yupelri |
| Pulmonx Corporation | $21.90 | 2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Alkermes, INC. | $21.77 | 2025 | Aristada, Lybalvi |
| Arbor Pharmaceuticals, INC. | $21.65 | 2021 | |
| Almatica Pharma LLC | $20.94 | 2021 | |
| Xeris Pharmaceuticals, INC. | $20.53 | 2022 | |
| Phadia US INC. | $19.46 | 2021 | |
| Heartflow, INC. | $17.95 | 2025 | |
| Organon LLC | $17.34 | 2025 | Nexplanon |
| Nestle Healthcare Nutrition INC. | $16.61 | 2023 | |
| Fidia Pharma USA INC. | $16.47 | 2022 | |
| Radius Health, INC. | $15.60 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $15.38 | 2024 | Eliquis |
| Phathom Pharmaceuticals, INC. | $14.99 | 2024 | Voquezna |
| Biodelivery Sciences International, INC. | $14.54 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $13.37 | 2019 | |
| Cardiovascular Systems INC. | $8.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ducato listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.